Meloxicam SBEβCD Inclusion Complex for Rapid Absorption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Meloxicam, a nonsteroidal anti-inflammatory drug, has poor aqueous solubility, leading to reduced bioavailability and delayed pain relief, which can be addressed by forming an inclusion complex with cyclodextrins like sulfobutyl ether β-cyclodextrin (SBEβCD) and administering it with a bicarbonate to enhance solubility and absorption.
Innovation Solution
The formation of an inclusion complex of meloxicam with SBEβCD and a bicarbonate, such as sodium bicarbonate, facilitates increased bioavailability and rapid absorption of meloxicam, when administered orally or intravenously, often in combination with rizatriptan for treating migraine and pain conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If meloxicam is administered in conventional formulations, then the drug structure and dosing regimen are simple, but the aqueous solubility is poor leading to reduced bioavailability and slow onset of pain relief
Solution Approach 1:
The patent uses cyclodextrins as intermediary carriers that form inclusion complexes with meloxicam. The cyclodextrin cavity accommodates the hydrophobic meloxicam molecule, while the hydrophilic exterior of cyclodextrin enhances water solubility. This intermediary structure resolves the contradiction by enabling both high bioavailability and rapid onset without altering the meloxicam molecule itself.
Solution Approach 2:
The patent changes the physical-chemical parameters of meloxicam by forming inclusion complexes with cyclodextrins. This transformation modifies the solubility characteristics and dissolution rate of meloxicam, converting it from a poorly soluble compound to a highly soluble complex that rapidly releases the drug at the administration site, thereby achieving both high bioavailability and fast onset of action.
2Ease of operation
If meloxicam is administered orally, then the administration route is simple and non-invasive, but the absorption rate is slow due to poor solubility
Solution Approach 1:
Cyclodextrins serve as mediators that enable rapid absorption while maintaining oral administration. The inclusion complex structure protects meloxicam during gastric transit and facilitates rapid dissolution in the intestinal environment, allowing simple oral dosing to achieve fast absorption rates comparable to or exceeding parenteral routes.
3Reliability
If conventional meloxicam formulations are used, then the formulation complexity is low, but the patient requires rescue medication due to inadequate response
Solution Approach 1:
The patent creates a composite pharmaceutical system combining meloxicam with cyclodextrin carriers and optional co-analgesics. This composite formulation ensures reliable pain relief by guaranteeing rapid and complete drug delivery, eliminating the need for rescue medication. The increased formulation complexity is justified by the significant improvement in treatment reliability and elimination of treatment failure.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly enhances the bioavailability and absorption of meloxicam, providing rapid and sustained pain relief, reducing the need for rescue medication and improving treatment outcomes in patients with inadequate responses to prior treatments.
Implementation Method 1
In aqueous solutions, cyclodextrins can form complexes (i.e., an inclusion complex) with drugs by incorporating the drug into the center/hydrophobic portion of the cyclodextrin ring
Implementation Method 2
administering it with a bicarbonate to enhance solubility and absorption
Data Source
AI summary
Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.